Macrocyclic sulfondiimine compounds

US10717749B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Ulrich Lücking · Berlin, DE
• Jens Geisler · Berlin, DE
• Daniel Hog · Düsseldorf, DE
• Arne Scholz · Berlin, DE
• Kirstin Petersen · Berlin, DE
• Philip Lienau · Berlin, DE
• Christian Stegmann · Berlin, DE
• Dorothee Andres · Potsdam, DE
• Kunzeng Zheng · Shanghai, CN
• Ping Gao · Portage, US
• Gang Chen · Sammamish, US
• Jiajun Xi · Shanghai, CN
• Simon Anthony HERBERT · Berlin, DE
• Gerhard Siemeister · Berlin, DE
• Nicolas Werbeck · Berlin, DE

Key dates

• Filing date: Sep 26, 2016
• Grant date: Jul 21, 2020
• Expiry date: Oct 14, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).